Literature DB >> 1763047

Blast crisis in a murine model of chronic myelogenous leukemia.

G Q Daley1, R A Van Etten, D Baltimore.   

Abstract

The P210bcr/abl protein is produced in cells from patients with Philadelphia chromosome-positive chronic myelogenous leukemia (CML). Retroviral transfer of the gene encoding P210bcr/abl into murine bone marrow induces a granulocytic leukemia that models the chronic phase of human CML. We have transferred the leukemic clone to syngeneic animals, albeit with surprising inefficiency, and have observed CML and clonally related acute leukemias of lymphoid or myeloid phenotype in some transplant recipients. These data show that murine CML can result from retroviral transfer of the bcr/abl gene into pluripotent hematopoietic stem cells, that infected clones repopulate poorly after adoptive transfer, and that these clones can give rise to acute leukemia, reflecting evolution to a phase resembling blast crisis in the human disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1763047      PMCID: PMC53129          DOI: 10.1073/pnas.88.24.11335

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  24 in total

Review 1.  Chronic myelogenous leukemia: recent advances.

Authors:  R E Champlin; D W Golde
Journal:  Blood       Date:  1985-05       Impact factor: 22.113

2.  A bcr-v-abl oncogene induces lymphomas in transgenic mice.

Authors:  I K Hariharan; A W Harris; M Crawford; H Abud; E Webb; S Cory; J M Adams
Journal:  Mol Cell Biol       Date:  1989-07       Impact factor: 4.272

3.  Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.

Authors:  J D Rowley
Journal:  Nature       Date:  1973-06-01       Impact factor: 49.962

4.  Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein.

Authors:  G Q Daley; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

5.  Developmental potential and dynamic behavior of hematopoietic stem cells.

Authors:  I R Lemischka; D H Raulet; R C Mulligan
Journal:  Cell       Date:  1986-06-20       Impact factor: 41.582

6.  Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

Authors:  M A Kelliher; J McLaughlin; O N Witte; N Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

7.  Isolation in a single step of a highly enriched murine hematopoietic stem cell population with competitive long-term repopulating ability.

Authors:  S J Szilvassy; P M Lansdorp; R K Humphries; A C Eaves; C J Eaves
Journal:  Blood       Date:  1989-08-15       Impact factor: 22.113

8.  Successful autografting in chronic myeloid leukaemia after maintenance of marrow in culture.

Authors:  M J Barnett; C J Eaves; G L Phillips; D K Kalousek; H G Klingemann; P M Lansdorp; D E Reece; J D Shepherd; G J Shaw; A C Eaves
Journal:  Bone Marrow Transplant       Date:  1989-07       Impact factor: 5.483

9.  bcr-abl oncogene renders myeloid cell line factor independent: potential autocrine mechanism in chronic myeloid leukemia.

Authors:  I K Hariharan; J M Adams; S Cory
Journal:  Oncogene Res       Date:  1988

10.  Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells.

Authors:  J McLaughlin; E Chianese; O N Witte
Journal:  Mol Cell Biol       Date:  1989-05       Impact factor: 4.272

View more
  18 in total

1.  Hematologic disease induced in BALB/c mice by a bcr-abl retrovirus is influenced by the infection conditions.

Authors:  A G Elefanty; S Cory
Journal:  Mol Cell Biol       Date:  1992-04       Impact factor: 4.272

2.  RNA binding protein MSI2 positively regulates FLT3 expression in myeloid leukemia.

Authors:  Ayuna Hattori; Daniel McSkimming; Natarajan Kannan; Takahiro Ito
Journal:  Leuk Res       Date:  2017-01-11       Impact factor: 3.156

3.  Insights into the pathophysiology and therapy of myeloproliferative neoplasms from mouse models.

Authors:  R A Van Etten
Journal:  Leuk Suppl       Date:  2014-12-17

Review 4.  Anticipating clinical resistance to target-directed agents : the BCR-ABL paradigm.

Authors:  Mohammad Azam; George Q Daley
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

Review 5.  Models of chronic myeloid leukemia.

Authors:  R A Van Etten
Journal:  Curr Oncol Rep       Date:  2001-05       Impact factor: 5.075

6.  Zebrafish as a model for cancer self-renewal.

Authors:  Myron S Ignatius; David M Langenau
Journal:  Zebrafish       Date:  2009-12       Impact factor: 1.985

7.  Illegitimate RAG-mediated recombination events are involved in IKZF1 Δ3-6 deletion in BCR-ABL1 lymphoblastic leukaemia.

Authors:  Y Dong; F Liu; C Wu; S Li; X Zhao; P Zhang; J Jiao; X Yu; Y Ji; M Zhang
Journal:  Clin Exp Immunol       Date:  2016-07-28       Impact factor: 4.330

8.  Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1.

Authors:  Shengqing Gu; Wayne W Chan; Golam Mohi; Joel Rosenbaum; Azin Sayad; Zhibin Lu; Carl Virtanen; Shaoguang Li; Benjamin G Neel; Richard A Van Etten
Journal:  Blood       Date:  2016-01-15       Impact factor: 22.113

9.  Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice.

Authors:  M L Gishizky; J Johnson-White; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

10.  Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.

Authors:  C Walz; N C P Cross; R A Van Etten; A Reiter
Journal:  Leukemia       Date:  2008-06-05       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.